ReviewCancers2022
Gastric Cancer Risk and Pathogenesis in
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 39 citations in OpenAlex.
- Docetaxel-oxaliplatin-capecitabine/5-fluorouracil (DOX/F) followed by docetaxel versus oxaliplatin-capecitabine/5-fluorouracil (CAPOX/FOLFOX) in HER2-negative advanced gastric cancers.JNCI cancer spectrum · 2024Trial
- Prevalence of Helicobacter pylori Exposure and Risk Factors Among BRCA1 and BRCA2 Carriers.International journal of cancer · 2026Article
- Gastric Epithelium from BRCA1 and BRCA2 Carriers Harbors Increased Double-Stranded DNA Damage and Enhanced Growth Potential.Molecular cancer research : MCR · 2026Article
- Progression after endoscopic treatment for type I gastric neuroendocrine tumors: A single-center retrospective study.World journal of gastroenterology · 2026Article
- Article
- The interplay of the microbiome, host genetics, and epigenetic modifications in gastric cancer.Frontiers in microbiology · 2026Review
- Associations between Pathogenic Germline Variants in BRCA and Non-Breast/Non-Ovarian Cancer Types in the German Population.Geburtshilfe und Frauenheilkunde · 2026Article
- Article
- Screening of the founder pathogenic variants BRCA1 and BRCA2 in Russian metropolitan women.BMC women's health · 2025Article
- Gastric epithelium frombioRxiv : the preprint server for biology · 2025Article
- Expanding the Genomic Landscape of HBOC and Cancer Risk Among Mutation Carriers.International journal of molecular sciences · 2025Article
- Olaparib Combined with Anti-PD1 Enhances Immunotherapy of Gastric Cancer Via NF-κB/c-Myc/PD-L1 Signaling.Digestive diseases and sciences · 2025Article
- Challenging the extended phenotype: HRD-negative salivary gland carcinoma in aFrontiers in oncology · 2025Article
- Article
- Diagnostics and Therapy for Malignant Tumors.Biomedicines · 2024Review
- BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients: A Review.JAMA oncology · 2024Review
- Untapped Potential of Poly(ADP-Ribose) Polymerase Inhibitors: Lessons Learned From the Real-World Clinical Homologous Recombination Repair Mutation Testing.World journal of oncology · 2024Article
- Prevalence of H. pylori and Gastric Intestinal Metaplasia in BRCA1 and BRCA2 Carriers.Cancer prevention research (Philadelphia, Pa.) · 2024Article
- Hereditary Gastrointestinal Tumor Syndromes: When Risk Comes with Your Genes.Current issues in molecular biology · 2024Review
- Predictive Value and Therapeutic Significance of Somatic BRCA Mutation in Solid Tumors.Biomedicines · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Carriers of a pathogenic germline variant (PV) in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.